- Home
- HFBL vs ACRV Comparison
HFBL vs ACRV Comparison
Compare HFBL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- ACRV
- Stock Information
- Founded
- HFBL 1924
- ACRV 2018
- Country
- HFBL United States
- ACRV United States
- Employees
- HFBL N/A
- ACRV N/A
- Industry
- HFBL Savings Institutions
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- HFBL Finance
- ACRV Health Care
- Exchange
- HFBL Nasdaq
- ACRV Nasdaq
- Market Cap
- HFBL 41.6M
- ACRV 47.8M
- IPO Year
- HFBL N/A
- ACRV 2022
- Fundamental
- Price
- HFBL $15.25
- ACRV $2.26
- Analyst Decision
- HFBL
- ACRV Buy
- Analyst Count
- HFBL 0
- ACRV 5
- Target Price
- HFBL N/A
- ACRV $14.67
- AVG Volume (30 Days)
- HFBL 2.4K
- ACRV 1.2M
- Earning Date
- HFBL 10-23-2025
- ACRV 11-13-2025
- Dividend Yield
- HFBL 3.54%
- ACRV N/A
- EPS Growth
- HFBL 35.20
- ACRV N/A
- EPS
- HFBL 1.47
- ACRV N/A
- Revenue
- HFBL $21,720,000.00
- ACRV N/A
- Revenue This Year
- HFBL N/A
- ACRV N/A
- Revenue Next Year
- HFBL N/A
- ACRV $805.34
- P/E Ratio
- HFBL $10.39
- ACRV N/A
- Revenue Growth
- HFBL 10.10
- ACRV N/A
- 52 Week Low
- HFBL $12.27
- ACRV $1.05
- 52 Week High
- HFBL $16.95
- ACRV $8.35
- Technical
- Relative Strength Index (RSI)
- HFBL 54.44
- ACRV 58.68
- Support Level
- HFBL $15.32
- ACRV $1.78
- Resistance Level
- HFBL $15.99
- ACRV $2.35
- Average True Range (ATR)
- HFBL 0.25
- ACRV 0.20
- MACD
- HFBL 0.02
- ACRV 0.01
- Stochastic Oscillator
- HFBL 39.50
- ACRV 69.83
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.